WESTON, Fla., Feb. 22, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that Stephen Marcus, M.D., Chief Executive Officer, will participate in the BIO CEO & Investor Conference being held February 26-27, 2024 in New York City.
During the conference, Dr. Marcus will conduct one-on-one meetings with registered investors, showcasing the Company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. Cantex is developing azeliragon, an oral inhibitor of the receptor for advanced glycation end products (known as RAGE). Cantex has ongoing Phase 2 clinical trials in top US and EU medical centers in glioblastoma, brain metastasis, metastatic pancreatic cancer, and breast cancer, and a Phase 3 randomized, placebo-controlled clinical trial in hospitalized patients with pneumonia.
Details of the event are as follows:
Event: | BIO CEO & Investor Conference |
Date & Time: | February 26-27, 2024 |
Location: | The New York Marriott Marquis, New York, NY |
Registration: |
About Azeliragon
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment. Azeliragon was discovered by and originally under development for Alzheimer's disease by vTv Therapeutics Inc. (NASDAQ: VTVT), from which Cantex licensed worldwide rights to azeliragon. Clinical safety data from these trials, involving more than 2,000 individuals dosed for periods up to 18 months, indicate that azeliragon is very well tolerated.
Cantex has multiple ongoing clinical trials as noted above. These trials are based on azeliragon's robust preclinical data as well as its extensive clinical safety information from randomized placebo-controlled clinical trials.
About Cantex Pharmaceuticals, Inc.
Cantex Pharmaceuticals, Inc. is a privately held, clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed. For more information, please visit www.cantex.com.
About vTv Therapeutics Inc.
vTv Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing oral, small molecule drug candidates, led by cadisegliatin (TTP399), a potentially transformative treatment for the reduction of hypoglycemic episodes in type 1 diabetes patients. To learn more please visit vtvtherapeutics.com.
Contact Data:
Tiberend Strategic Advisors, Inc.
Investors
Daniel Kontoh-Boateng
+1 862-213-1398
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Casey McDonald
+1 646-577-8520
This email address is being protected from spambots. You need JavaScript enabled to view it.
Cantex Pharmaceuticals, Inc.
Stephen G. Marcus, M.D.
+1 954-315-3660
This email address is being protected from spambots. You need JavaScript enabled to view it.
Juan F. Rodriguez
+1 954-315-3660
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$17.01 |
| Daily Change: | -0.49 -2.80 |
| Daily Volume: | 3,910 |
| Market Cap: | US$44.570M |
May 15, 2025 March 20, 2025 March 17, 2025 December 09, 2024 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
